TriNutra announces new U.S. patent of its branded black seed oil ingredients

Photo © Shutterstock.com/Ulada

Ahead of Expo West 2024, TriNutra has announced a recent U.S. patent for the unique composition of its branded ingredients, ThymoQuin, B’utyQuin, and ThymoQuin-OCare. These ingredients are made with the company’s cold-pressed black seed (Nigella sativa; NS) oil. According to the company, the patent states:

“This present invention is directed to a cold-pressed NS oils containing concentrations of thymoquinone (TQ) that are significantly higher than obtained in prior NS oils of this type. Since many of the therapeutic and health-promoting activities of NS oils are related to their TQ content, the oil compositions of the present invention provide a significant technical advance since, on the one hand, they possess high concentrations of the active agent (TQ), while on the other hand, maintaining a full spectrum oil and the inherent composition of the oils in the seeds. In addition, they are free from the safety, regulatory, cost-related, and other disadvantages associated with prior high-TQ NS extracts produced by using selective solvent extraction techniques.”

Thymoquinone is the key active of NS which can be unstable in the presence of antioxidants, such as free fatty acids, TriNutra’s goal has been to produce a standardized and stable. TriNutra oil is standardized to 3% thymoquinone, and does not exceed 1.25% free fatty acid. “Our unique formulation achieved our goal beyond expectations, tapping the success with increased stability, bioavailability, and efficacy of black seed oil,” said Morris Zelkah, CEO of TriNutra, in a press release. “ThymoQuin has brought innovation to this ancient ingredient with several published clinical trials on its health benefits and efficacy, and numerous global patents back it for its composition, stability, bioavailability, and use. We are incredibly proud of yet another achievement for ThymoQuin and its potential in human health.”